Skip to content

Evolutionary Genomics, Inc.: 10-K filed 2021-03-31

What Evolutionary Genomics, Inc. reported in its annual report filed 2021-03-31 (fiscal FY 2020): 33 published measures, 80 facts as tagged in accession 0001553350-21-000252.

This filing

Form
10-K (annual report)
Filed
2021-03-31
Fiscal period
fiscal FY 2020
Accession
0001553350-21-000252 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Evolutionary Genomics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-12-313,992,699USD
At 2019-12-314,242,637USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-12-312,248,995USD
At 2019-12-311,006,768USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-12-31-1,825,890USD
At 2020-09-30-169,665USD
At 2020-06-30-760,480USD
At 2020-03-31-520,611USD
At 2019-12-31-333,725USD
At 2019-09-30-135,605USD
At 2019-06-3027,268USD
At 2019-03-31212,068USD
At 2018-12-31403,587USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-12-31215,836USD
At 2019-12-3145,441USD
At 2018-12-31131,406USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-10-01 to 2020-12-31-1,711,154USD92
2020-01-01 to 2020-12-31-1,711,883USD366
2020-07-01 to 2020-09-30535,885USD92
2020-04-01 to 2020-06-30-294,798USD91
2020-01-01 to 2020-03-31-241,816USD91
2019-10-01 to 2019-12-31-232,107USD92
2019-01-01 to 2019-12-31-793,140USD365
2019-07-01 to 2019-09-30-162,873USD92
2019-04-01 to 2019-06-30-189,363USD91
2019-01-01 to 2019-03-31-208,797USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-2,297,317USD366
2019-01-01 to 2019-12-31-625,980USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-01-01 to 2020-12-3112,500USD366
2019-01-01 to 2019-12-31122,686USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-12-312,320,099USD366
2019-01-01 to 2019-12-31540,015USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-12-31147,613USD366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-12-31-15,083,552USD
At 2019-12-31-13,371,669USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-987,353USD366
2019-01-01 to 2019-12-3131,907USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-12-3150,763USD
At 2019-12-3188,882USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-01-01 to 2020-12-31219,718USD366
2019-01-01 to 2019-12-3155,828USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-2,879,795USD366
2019-01-01 to 2019-12-31-774,825USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-12-31277,593USD
At 2019-12-31118,163USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-12-313,164USD
At 2019-12-3119,415USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2020-12-313,664,343USD
At 2019-12-314,035,592USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2019-12-316,845USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-01-01 to 2020-12-312,892,295USD366
2019-01-01 to 2019-12-31897,511USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-01-01 to 2020-12-311,793,145USD366
2019-01-01 to 2019-12-31472,613USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-12-315,881,898shares
At 2019-12-315,881,898shares
At 2019-09-305,881,898shares

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2020-12-31503,665USD
At 2019-12-31503,665USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2020-12-31452,902USD
At 2019-12-31414,783USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2020-12-31903,283USD
At 2019-12-3110,860USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2019-12-31987,353USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-2,699,236USD366
2019-01-01 to 2019-12-31-761,233USD365

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-1,997,450USD366
2019-01-01 to 2019-12-31-1,062,519USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-01-01 to 2020-12-31603,632USD366
2019-01-01 to 2019-12-31219,070USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-01-01 to 2020-12-3138,119USD366
2019-01-01 to 2019-12-3138,119USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2020-01-01 to 2020-12-31409,368USD366
2019-01-01 to 2019-12-3140,721USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-01-01 to 2020-12-31180,559USD366
2019-01-01 to 2019-12-3113,592USD365

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-987,353USD366
2019-01-01 to 2019-12-3131,907USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-6,845USD366
2019-01-01 to 2019-12-31-33,594USD365

Inspect the source

Entity
Evolutionary Genomics, Inc. / CIK 0000884363
Captured
SEC response SHA-256
a2b66772c1d0ab2271c82d2191d0de1fc92fc9df77b277aa7e747ea7abf31177

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000884363.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))